Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teplizumab vs ATG in Stage 2 Type 1 Diabetes
NCT07216391Phase 2Recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jul 2026
- Primary completion
- Nov 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of teplizumab, antithymocyte globulin in type 1 diabetes mellitus (T1D), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Started Jul 2026; status: recruiting.
02
Drugs
teplizumabantithymocyte globulin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07216391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07216391.